Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment.

NCT06855849 is registered in ClinicalTrials.gov with Yonsei University as lead sponsor.

NCT NCT06855849
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06855849 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment.
Lead sponsor
Yonsei University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
May 31, 2025
Completion date
December 31, 2027
Enrollment
85 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ras/braf wild-type advanced colorectal cancer patients